Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. - Wikidata - awgldk - TriplyDB

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

http://www.wikidata.org/entity/Q34067962

about

Advances in understanding and managing bullous pemphigoid Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid Neonatal Autoimmune Blistering Disease: A Systematic Review.Intravenous immunoglobulin as clinical immune-modulating therapy.Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.Autoimmune blistering diseases in females: a review.Bullous pemphigoid in infants: characteristics, diagnosis and treatment.The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study Randomized controlled trials needed for bullous pemphigoid interventions.Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.Rituximab for autoimmune blistering diseases: recent studies, new insights.Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.BP180- and BP230-specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid?Blistering disease: insight from the hemidesmosome and other components of the dermal-epidermal junction.Outcome measures for autoimmune blistering diseases.Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland.Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment.Validation studies of outcome measures in pemphigus.Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis.Measurement of disease severity in cutaneous autoimmune diseases.Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.[Bullous pemphigoid].Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid.Variation of the epidermal expression of glucocorticoid receptor-beta as potential predictive marker of bullous pemphigoid outcome.Azathioprine monotherapy in autoimmune blistering diseases: A feasible option for mild to moderate cases.Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center.An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.Immunopathological characteristics of patients with bullous pemphigoid and neurological disease.Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid.S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid.Prognostic clinical factors associated with remission and relapse in bullous pemphigoid.Clinical and immunological features and outcome of anti-p200 pemphigoid.Bullous pemphigoid developed in a patient with prurigo nodularis.Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.

P2860

Q26766192-27273877-5CEB-4DDE-BE11-A64398EE28A9 Q27346806-71060DA3-3BCB-4308-910E-6C0C899A4690 Q30251572-66AA5703-9348-436A-8C4D-979E7E3EE55B Q33420267-89783437-AED1-4A29-AF3E-18C94EA6749F Q33592137-B2B8BFA7-E3FE-4ED9-A982-74770FA86390 Q33640302-4BBAAE81-F5B8-4270-AB75-0A719D11542F Q34998115-824159AC-BE5D-4C8A-AF95-A785D5B55926 Q35010914-377505BE-8FF8-4969-94CD-61F0AB09BC9E Q35068151-F7D87B94-7EF5-452F-AC0A-EE54B9BA1510 Q35097273-157ED4E7-8BA2-42A9-94C7-36959B61CF9A Q36367126-E69EAEFD-1908-42A2-A736-451B510B9D94 Q36446786-63CC67B0-BC32-4612-9EF7-93D7741525BB Q36751954-C127E1AC-C6F2-41B0-8D94-3167E0CA4775 Q37326405-D868C4A3-E1C2-431B-9F12-6D7761BB1C89 Q38193888-0CA3B410-A97C-465B-9DEF-811CD1A2E1D1 Q38287144-239B7406-B769-498D-A3C8-F053B9EB1F1B Q38307352-D7EEA9EA-F54F-46AB-9F29-27ECC618CD65 Q38602702-746AAEF7-1096-4666-93D7-B186517C4F04 Q38752194-A8EEEED5-CD92-46E1-8ED2-74DB0427B563 Q38793267-DC594518-5B78-4E25-AA21-D69A9B879418 Q39464721-6FC06448-1CD4-4E73-9EC3-DB50C7891CFE Q41458646-6D583324-3F6A-4426-854A-34E8F1CE8D70 Q41558860-E2E5AB3E-5B31-4322-B5A0-DF27A04F042B Q43424403-36EC6E3B-64CD-49B8-A603-88E212295727 Q44346755-42562BA8-849E-4D09-85D1-F4C6FBBE233E Q45007774-F35405D4-9B0C-42EC-B09E-DA4E3378A031 Q46244822-392BCB8D-523C-436D-ADD3-2C1574666A77 Q47830273-0D68D593-3A5F-40E5-BF41-DCD8C367CDC7 Q48102560-DEE509BD-FC04-48CB-8F94-F9426949FB9E Q48136064-7CEE0A74-24FC-4DF8-8D34-86E6CC87E68A Q48151357-679CF726-83C8-47F3-9E7D-BDA2BF92F4A0 Q48157175-A4531348-C015-423D-B3AE-D27353FBA571 Q50716922-B3AFB523-2506-4E8F-89E4-CB89E341D529 Q52845120-BB2F5E1A-D4C9-4782-B346-FD2CE5B7FA60 Q52863877-D1F81FCD-ACAC-4CE3-A5DC-F8E7578848A7 Q52865044-3A52D21E-5C14-4A61-97B3-57B9C735B0FB Q53065575-B83800A1-272E-4078-B7DE-5C3448EA2BDB Q53131535-E4491628-84DE-44D7-BDB5-D9BD8468DCCF Q53962249-D1614258-C980-4416-A574-29E3F8861353 Q54940292-9AF6E34C-B122-4358-A84D-E0A1A9BBAFE6

P2860

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

http://www.wikidata.org/entity/Q34067962

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Definitions and outcome measur ...... nternational panel of experts.

@ast

Definitions and outcome measur ...... nternational panel of experts.

@en

Definitions and outcome measur ...... nternational panel of experts.

@nl

type

label

Definitions and outcome measur ...... nternational panel of experts.

@ast

Definitions and outcome measur ...... nternational panel of experts.

@en

Definitions and outcome measur ...... nternational panel of experts.

@nl

prefLabel

Definitions and outcome measur ...... nternational panel of experts.

@ast

Definitions and outcome measur ...... nternational panel of experts.

@en

Definitions and outcome measur ...... nternational panel of experts.

@nl

P1433

Q34067962-B2CDBA6B-4A6E-4C23-85CA-0A9DA06DE01D

P1476

Q34067962-CCB327B1-F6B0-4D83-8CDE-057C94A5E504

P2093

Q34067962-00A29FAA-0094-49DA-B552-14A52BFB4D51

Q34067962-03E3354E-261E-49A8-BB57-F98D79E561B6

Q34067962-0F67A7B1-1E3C-4012-A703-5E2B4A91F164

Q34067962-1342F99F-94EC-4F01-A197-DCA4EB50D406

Q34067962-16440DAF-5D7F-4EE4-ACFD-774AE1FEF344

Q34067962-1BCF8AB3-F325-422C-B663-BB7716E15ABF

Q34067962-1C90E64A-94F4-46A0-906B-7E747C1797EA

Q34067962-1EA015D2-D0FC-44F5-A33C-4C1D6F193C34

Q34067962-3EEF1EF2-5780-4819-A1A1-77873BD61651

Q34067962-48B3E894-001F-45CC-9A32-CCE1E4E43DB6

P2860

Q34067962-01BBD96F-3B64-4E54-AF74-4693153B1E1D

Q34067962-2B8EC473-8DAA-4001-AE2E-83F1D4748262

Q34067962-56551EDD-D203-4197-AB88-931B20C77A24

Q34067962-578AC94F-5FE9-489E-9345-AE8759A65403

Q34067962-67F31A0C-B0BC-4B61-9B6D-7AA0FEBE08F7

Q34067962-7589B9D7-0711-438D-B14E-C826360CD68C

Q34067962-834E93FD-D327-49E5-B5AC-BD6B909E1C3E

Q34067962-B1E0BA0E-B8DB-47FD-B747-66B8B96E7FD6

P304

Q34067962-56F97C90-C12C-4F3A-A030-8DE3C57E4733

P31

Q34067962-35549435-0C9B-4024-BCA4-1394AA6362B5

P356

Q34067962-504B34CE-D36C-4CDD-A544-ED74B226F08A

P407

Q34067962-4D17C322-DE97-46F7-84F7-8958A50F58CC

P433

Q34067962-C44FD1C9-4D9D-4A26-BE6E-51FA5F10F299

P478

Q34067962-C6CCEAC1-728C-43CE-80DE-776C827011CF

P50

Q34067962-0CFF2202-EB3D-4392-906F-D92A644C05B6

Q34067962-3653002A-A75A-412E-AB20-EA362CAB4F6B

Q34067962-51F28A04-0586-4E9F-87F2-AD7C79F62F50

Q34067962-9E9DAACD-EEF1-433C-9FC0-6B7754AC4F07

Q34067962-A2B2A826-5ED7-4A89-A2CC-7989217CC098

Q34067962-C2521EC1-A605-4A97-BEF7-AF7924FD2840

Q34067962-D4DF935F-EC70-4A2C-9389-A6A8D4D4574A

Q34067962-DBAF8612-2CC4-4D94-92DC-61CE8CF5FFDF

Q34067962-E8EA6880-F8D4-4A16-A104-61BC9628E55A

P577

Q34067962-0A03E314-5E37-4957-B92C-59153D8AA96B

P5875

Q34067962-6B789CCA-3985-4E5F-A71D-6BF6B1A6C453

P698

Q34067962-96C29F9B-C218-4386-B38A-8C5D814F10A3

P932

Q34067962-9C3DEC52-9B81-4143-BAF8-E27F245D7A81

P356

J.JAAD.2011.06.032

P1433

Journal of the American Academy of Dermatology

P1476

Definitions and outcome measur ...... international panel of experts

@en

P2093

Aimee S Payne

http://www.w3.org/2001/XMLSchema#string

Amit G Pandya

http://www.w3.org/2001/XMLSchema#string

Animesh A Sinha

http://www.w3.org/2001/XMLSchema#string

Benjamin Bince

http://www.w3.org/2001/XMLSchema#string

Benjamin S Daniel

http://www.w3.org/2001/XMLSchema#string

Daniel Mimouni

http://www.w3.org/2001/XMLSchema#string

David Rubenstein

http://www.w3.org/2001/XMLSchema#string

David Sirois

http://www.w3.org/2001/XMLSchema#string

David Woodley

http://www.w3.org/2001/XMLSchema#string

Dedee F Murrell

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for bullous pemphigoid

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Reliability and convergent validity of two outcome instruments for pemphigus.

Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.

A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.

Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group.

Nicotinamide and tetracycline therapy of bullous pemphigoid.

P304

479-485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JAAD.2011.06.032

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Takashi Hashimoto

Masayuki Amagai

Robert Swerlick

Janet A. Fairley

Branka Marinović

P577

2011-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51773390

http://www.w3.org/2001/XMLSchema#string

P698

22056920

http://www.w3.org/2001/XMLSchema#string

P932

3883429

http://www.w3.org/2001/XMLSchema#string